On November 14, 2022, MBX Biosciences, Inc., a clinical-stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, announced the closing of a $115 million Series B financing. The Series B financing was led by Wellington Management, with participation from RA Capital Management and Norwest Venture Partners along with existing investors Frazier Life Sciences, New Enterprise Associates (NEA), and OrbiMed. Wilson Sonsini Goodrich & Rosati advised MBX Biosciences on patent matters related to the transaction.

Proceeds of the financing will support MBX into early 2025 as it develops transformative therapeutics PEPs™, designed to overcome limitations of traditional peptide therapeutics. This includes continued clinical advancement of its lead product candidate, MBX 2109, which is in development for the treatment of hypoparathyroidism and currently in a Phase 1 clinical trial. In addition, proceeds will support the company’s preclinical pipeline, led by MBX 1416, and discovery programs in endocrine diseases.

The Wilson Sonsini patents and innovations team that advised MBX Biosciences on the transaction included Uale Taotafa, Michael Hostetler, and Sara Butterfield.

For more information, please see MBX Biosciences' press release.